The EU’s medicines regulator committee is meeting on Wednesday to decide whether to authorise a second coronavirus vaccine developed by biotechnology company Moderna in hand with the US National Institutes of Health, Euronews reports.

Many hope that with multiple vaccines authorised in the EU, those who are vulnerable to the disease will be vaccinated more quickly.

Vaccinations began in the EU on December 27 after the bloc authorised the Pfizer/BioNTech vaccine.

The company had enrolled 30,000 participants in its phase three trials and announced in November that the Moderna vaccine was more than 94% effective. Also, the company vaccine is easier to handle than the Pfizer vaccine because it doesn’t need to be stored at ultra-frozen temperatures.

The US first authorised the use of the Moderna vaccine in December. The EU has ordered up to 160 million doses of the vaccine.